scholarly journals The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients

Oncogene ◽  
2011 ◽  
Vol 31 (33) ◽  
pp. 3796-3806 ◽  
Author(s):  
A Neeb ◽  
S Wallbaum ◽  
N Novac ◽  
S Dukovic-Schulze ◽  
I Scholl ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cell ◽  
Cell Motility ◽  
Cancer Patients ◽  
Immediate Early Gene ◽  
Early Gene ◽  
Immediate Early ◽  
Poor Survival ◽  
Tumor Cell Motility ◽  
Colorectal Cancer Patients

High Expression of sLex Associated with Poor Survival in Argentinian Colorectal Cancer Patients

2014 ◽  
Vol 29 (1) ◽  
pp. e30-e39 ◽  
Author(s):  
Ariel Zwenger ◽  
Martin Rabassa ◽  
Sandra Demichelis ◽  
Gabriel Grossman ◽  
Amada Segal-Eiras ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Normal Mucosa ◽  
Poor Survival ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Colorectal Cancer Patients

Aim Colorectal cancer (CRC) is one of the most prevalent malignancies in Argentina with 11,043 new cases and 6,596 deaths estimated to have occurred in 2008. The present study was developed to clarify the differential expression of MUC1, MUC2, sLex, and sLea in colorectal cancer patients and their relationship with survival and clinical and histological features. Methods Ninety primary tumor samples and 43 metastatic lymph nodes from CRC patients were studied; follow-up was documented. Twenty-six adenoma and 68 histological normal mucosa specimens were analyzed. An immunohistochemical approach was applied and statistical analysis was performed. Results In tumor samples, MUC1, sLea, and sLex were highly expressed (94%, 67%, and 91%, respectively); also, we found a significantly increased expression of the 3 antigens in primary tumors and metastatic lymph nodes compared with normal mucosa and adenomas. MUC2 was expressed in 52% of both normal mucosa and CRC samples; this reactivity significantly decreased in metastatic lymph nodes (p<0.05). A multiple comparison analysis showed that MUC1 and sLex discriminated among 3 groups: normal, adenoma, and CRC tissues. The increase of sLex expression showed an association with recurrence, and survival analysis showed that a high sLex staining was significantly associated with a poor survival. By multivariate analysis MUC1 inmunoreactivity correlated positively and significantly with tumor size, while MUC2 expression showed the opposite correlation. Conclusions The correlation of sLex overexpression in primary tumors and metastatic lymph nodes, the discrimination among the normal, adenoma, and CRC groups based on sLex expression, as well as its association with recurrence and survival, all suggest a prognostic role of sLex in Argentinian CRC patients.

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

2011 ◽  
Vol 4 ◽  
pp. CGM.S7113 ◽  
Author(s):  
Ozgur Kemik ◽  
Ahu Sarbay Kemik ◽  
Aziz Sümer ◽  
Sevim Purisa ◽  
A. Cumhur Dulger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Stage Ii ◽  
Vascular Endothelial ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

scholarly journals High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients

2015 ◽  
Vol 14 (1) ◽  
pp. 38 ◽  
Author(s):  
Katharina Ilm ◽  
Wolfgang Kemmner ◽  
Marc Osterland ◽  
Susen Burock ◽  
Gudrun Koch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Poor Survival ◽  
Colorectal Cancer Patients

Elevated serum VEGF levels in colorectal cancer patients correlate with poor survival

2001 ◽  
Vol 37 ◽  
pp. S304 ◽  
Author(s):  
A. Karayiannakis ◽  
K. Syrigos ◽  
A. Zbar ◽  
N. Baibas ◽  
D. Tsioulos ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Poor Survival ◽  
Colorectal Cancer Patients

scholarly journals BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Jing Chen ◽  
Fang Guo ◽  
Xin Shi ◽  
Lihua Zhang ◽  
Aifeng Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Kras Codon

58 Mutational Analysis of Circulating Tumor Cell Subpopulations From Colorectal Cancer Patients and Correlation With Primary Tumor Tissue

2015 ◽  
Vol 148 (4) ◽  
pp. S-17
Author(s):  
Maria Gazouli ◽  
Anna Lyberopoulou ◽  
Penelope Bouziotis ◽  
Apostolos Papalois ◽  
Nikolaos I. Nikiteas ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cell ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Tissue ◽  
Mutational Analysis ◽  
Circulating Tumor Cell ◽  
Cell Subpopulations ◽  
Colorectal Cancer Patients

Clinical significance of serum angiopoietin-like protein 2 in colorectal cancer patients.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 417-417
Author(s):  
Takahito Kitajima ◽  
Yuji Toiyama ◽  
Tadanobu Shimura ◽  
Shozo Ide ◽  
Hiroki Imaoka ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cell ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Staining Intensity ◽  
High Serum ◽  
Highly Correlated ◽  
Colorectal Cancer Patients

417 Background: Angiopoietin-like protein 2 (ANGPTL2) is a secreted protein belonging to the angiopoietin family. It has been reported to act as a causative mediator of chronic inflammation and metabolic abnormalities. ANGPTL2 increases inflammatory carcinogenesis in several cancers, and its expression in tumor cells is highly correlated with the frequency of tumor cell metastasis through increased tumor angiogenesis and tumor cell epithelial-to-mesenchymal transitions. However, to our own knowledge, clinical significance of serum ANGPTL2 in cancer patients remains unknown. The aim of this study was to quantify serum ANGPTL2 level using ELISA, and to evaluate its clinical and prognostic significance in patients with colorectal cancer (CRC). Methods: We quantified serum ANGPTL2 levels from 194 CRC patients and normal 48 controls (NC) by ELISA. Next, we investigated ANGPTL2 expression in matched CRC tissues (n=194) by immunohistochemistry (IHC) to identify the source of circulating ANGPTL2. The IHC score of ANGPTL2 was determined on the basis of both staining intensity and the percentage of positive cells. Results: Serum ANGPTL2 levels were significantly higher in CRC than in NC (p<0.01) and gradually increased according to TNM stage progression. Serum ANGPTL2 levels discriminated CRC from NC with high accuracy (AUC=0.837). High serum ANGPTL2 was significantly associated with larger tumor size (p=0.03), undifferentiated adenocarcinoma (p=0.03), advanced T stage (p<0.01), peritoneal metastasis (p<0.01). In addition, Kaplan–Meier curves revealed that high serum ANGPTL2 were significantly associated with poor disease free survival (p=0.01) and overall survival (p=0.03). Interestingly, ANGPTL2 levels in serum from CRC patients closely correlated with IHC scores of cytoplasmic ANGPTL2 expression in matched CRC tissues (r=0.14, p=0.03). Conclusions: Serum ANGPTL2, which might be derived from primary CRC tumor, has strong potential to serve as a noninvasive biomarker for CRC diagnosis and prognosis.

Sign in / Sign up

Export Citation Format

Share Document